AmpliPhi advances phage in clinic to address microbial infections

February 8, 2017 Christoph Graener

Using cocktails of bacteriophages to attack bacterial infections, San Diego-based AmpliPhi announced progress in Phase I studies of its lead program. Company CEO Scott Salka explains to Mike Ward, Informa Pharma Intelligence’s insights global director of content, how he is looking to secure sufficient capital to support the Phase II development of its lead program against chronic rhinosinusitis while advancing other candidate products.

Interviewer: Mike Ward – Global Director of Content, Informa Pharma Insights
Interviewee: Scott Salka – CEO, AmpliPhi BioSciences

Previous Article
Q BioMed plans to accelerate up to four more assets

Established in June 2015, Q BioMed, the NYC-based biomedical acceleration development company, is looking t...

Next Article
Refocusing Tarveda on tumor-targeted mini-drug conjugates

In the past 18 months, Tarveda Therapeutics has been refocusing its efforts on Pentarins, its miniaturized ...